Danish diabetes care giant Novo Nordisk (NOV: N) today announced positive headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) Phase IIIa trials with once-weekly insulin icodec, edging the firm’s shares up 1.35 to 779.9 kroner.
ONWARDS 1 is a Phase IIIa, 78-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec versus insulin glargine U100 (insulin glargine) – marketed by Sanofi (Euronext: SAN) as Lantus, both in combination with non-insulin anti-diabetic treatment, in 984 insulin-naïve people with type 2 diabetes.
The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared to insulin glargine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze